30 minutes
The world of precision medicine has evolved dramatically over the years, with targeted treatment for specific patients dating back 2,500 years to Hippocrates. Although genetic and biomarker testing to guide treatment is possible, and in theory should improve care while lowering costs, barriers to widespread adoption remain. Hear from expert panelists as they offer competing views on the shifting paradigm, from biohackers and ultra-rare disease, to more mainstream targeting. How small is too small?


Jennifer Levin Carter - Healthcare Executive, Board member and Entrepreneur
Marion Dorsch - Chief Scientific Officer, Blueprint Medicines
Tamar Thompson - Vice President, U.S. Government Affairs, Alexion Pharmaceuticals, Inc.
Timothy Yu - Assistant Professor in Pediatrics, Harvard Medical School
Name Audience
Science Track